Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-132857 · Präparat HOS-097310

9 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration Telithromycin Telithromycine: Not recommended. Clarithromycin AUC: ↑ 2-fold Contraindicated in patients with Cmax: ↑1.5-fold severe renal impairment due to the Potential ↑in plasma concentrations of risk of QT interval prolongation and clarithromycin serious hepatic adverse reactions (see section 4.3). Isavuconazole AUC: ↑ 5-fold Not recommended due to increased Cmax: ↑ 1.1 -fold risk of isavuconazole adverse reactions, please consult isavuconazole SmPC Praziquantel ↑in plasma concentrations of Careful monitoring. praziquantel have been observed Dose adjustment of praziquantel may be required. Antimigraine Drugs Ergots alkaloids such as Potential ↑in plasma concentrations of Contraindicated due to the increased dihydroergotamine, ergot alkaloids risk of ergotism and other serious ergometrine vasospastic adverse reactions (see (ergonovine), section 4.3). ergotamine, methylergometrine (methylergonovine) Eletriptan Eletriptan: Not recommended. AUC: ↑ 5.9-fold Cmax: ↑ 2.7-fold Antineoplastics Irinotecan Irinotecan: Contraindicated due to an alteration AUC: ↑ 2.1-fold of the metabolism of this medicinal product (see section 4.3). Sunitinib Sunitinib Not recommended due to the risk of Dasatinib AUC: ↑ 1.5-fold increased exposure to these medicinal Lapatinib Cmax: ↑ 1.5-fold products and QT prolongation. Nilotinib Lapatinib: Erlotinib AUC: ↑ 3.6-fold Dabrafenib Nilotinib: Cabozantinib AUC: ↑ 3.0-fold Erlotinib: AUC: ↑ 1.9-fold Cmax: ↑ 1.7-fold Dasatinib ↑in plasma concentrations of Dasatinib have been observed Dabrafenib AUC: ↑ 1.7-fold Cmax: ↑ 1.3-fold Cabozantinib AUC: ↑ 1.4-fold Cmax: ↔ Ibrutinib Ibrutinib: Not recommended as it may increase AUC: ↑ 24-fold ibrutinib-related toxicity. Cmax: ↑ 29-fold

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): praziquantel (HOS-132858) dasatinib (HOS-086217) isavuconazole (HOS-085186) methylergonovine (HOS-086155) dabrafenib (HOS-109452) ergot alkaloids (HOS-108807) telithromycin (HOS-084523) lapatinib (HOS-122565) clarithromycin (HOS-084517) erlotinib (HOS-113527) eletriptan (HOS-132859) sunitinib (HOS-109453) ergotamine (HOS-086154) irinotecan (HOS-112102) ergonovine (HOS-086153) cabozantinib (HOS-109450) nilotinib (HOS-086218) dihydroergotamine (HOS-086152) ibrutinib (HOS-086226)